Cara-Lynne Schengrund All publications ( 38 ) Blome MC. Schengrund CL. Multivalent binding of ricin to bovine serum albumin-based neoglycoconjugates. 2008 Jun 1. Toxicon. 51(7):1214-24. Petro KA. Schengrund CL. Membrane Raft Disruption Promotes Axonogenesis in N2a Neuroblastoma Cells. 2008 Feb 29. Neurochem Res. . Hartmann SU. Wigdahl B. Neely EB. Berlin CM. Schengrund CL. Lin HM. Howett MK. Biochemical analysis of human milk treated with sodium dodecyl sulfate, an alkyl sulfate microbicide that inactivates human immunodeficiency virus type 1. 2006 Feb. J Hum Lact. 22(1):61-74. National Institute of Child Health and Human Development National Institute of Allergy and Infectious Diseases Petro KA. Dyer MA. Yowler BC. Schengrund CL. Disruption of lipid rafts enhances activity of botulinum neurotoxin serotype A. 2006 Dec 15. Toxicon. 48(8):1035-45. Schengrund CL. Glycoconjugates: roles in neural diseases caused by exogenous pathogens. 2006 Aug. CNS Neurol Disord Drug Targets. 5(4):381-9. National Institute of Neurological Disorders and Stroke Rosa Borges A. Schengrund CL. Dendrimers and antivirals: a review. 2005 Sep. Curr Drug Targets Infect Disord. 5(3):247-54. National Institute of Neurological Disorders and Stroke Stine R. Pishko MV. Schengrund CL. Comparison of glycosphingolipids and antibodies as receptor molecules for ricin detection. 2005 May 1. Anal Chem. 77(9):2882-8. National Institute for Biomedical Imaging and Bioengineering Urdaneta S. Wigdahl B. Neely EB. Berlin CM. Schengrund CL. Lin HM. Howett MK. Inactivation of HIV-1 in breast milk by treatment with the alkyl sulfate microbicide sodium dodecyl sulfate (SDS). 2005. Retrovirology. 2(1):28. National Institute of Child Health and Human Development National Institute of Allergy and Infectious Diseases Kensinger RD. Catalone BJ. Krebs FC. Wigdahl B. Schengrund CL. Novel polysulfated galactose-derivatized dendrimers as binding antagonists of human immunodeficiency virus type 1 infection. 2004 May. Antimicrob Agents Chemother. 48(5):1614-23. National Institute of Neurological Disorders and Stroke Kensinger RD. Yowler BC. Benesi AJ. Schengrund CL. Synthesis of novel, multivalent glycodendrimers as ligands for HIV-1 gp120. 2004 Mar-Apr. Bioconjug Chem. 15(2):349-58. National Institute of Neurological Disorders and Stroke Stine R. Pishko MV. Schengrund CL. Heat-stabilized glycosphingolipid films for biosensing applications. 2004 Jul 20. Langmuir. 20(15):6501-6. National Institute for Biomedical Imaging and Bioengineering Yowler BC. Schengrund CL. Botulinum neurotoxin A changes conformation upon binding to ganglioside GT1b. 2004 Aug 3. Biochemistry. 43(30):9725-31. Yowler BC. Schengrund CL. Glycosphingolipids-sweets for botulinum neurotoxin. 2004. Glycoconj J. 21(6):287-93. Schengrund CL. "Multivalent" saccharides: development of new approaches for inhibiting the effects of glycosphingolipid-binding pathogens. 2003 Mar 1. Biochem Pharmacol. 65(5):699-707. National Institute of Neurological Disorders and Stroke Yowler BC. Kensinger RD. Schengrund CL. Botulinum neurotoxin A activity is dependent upon the presence of specific gangliosides in neuroblastoma cells expressing synaptotagmin I. 2002 Sep 6. J Biol Chem. 277(36):32815-9. National Institute of Neurological Disorders and Stroke Jurasinski CV. Lieth E. Dang Do AN. Schengrund CL. Correlation of cleavage of SNAP-25 with muscle function in a rat model of Botulinum neurotoxin type A induced paralysis. 2001 Sep. Toxicon. 39(9):1309-15. National Institute of Neurological Disorders and Stroke Yowler BC. Stoehr SA. Schengrund CL. Oxidation and base-catalyzed elimination of the saccharide portion of GSLs having very different polarities. 2001 Apr. J Lipid Res. 42(4):659-62. National Institute of Neurological Disorders and Stroke Schengrund CL. Kovác P. UDP-6-deoxy-6-fluoro-alpha-D-galactose binds to two different galactosyltransferases, but neither can effectively catalyze transfer of the modified galactose to the appropriate acceptor. 1999 Jun 30. Carbohydr Res. 319(1-4):24-8. National Institute of Neurological Disorders and Stroke Schengrund CL. Kovác P. A simple, nonenzymatic method for desialylating polysialylated ganglio-N-tetraose series gangliosides to produce GM1. 1999 Jan. J Lipid Res. 40(1):160-3. National Institute of Neurological Disorders and Stroke Thompson JP. Schengrund CL. Inhibition of the adherence of cholera toxin and the heat-labile enterotoxin of Escherichia coli to cell-surface GM1 by oligosaccharide-derivatized dendrimers. 1998 Sep 1. Biochem Pharmacol. 56(5):591-7. National Institute of Neurological Disorders and Stroke Schengrund CL. Mummert CM. Exogenous gangliosides. How do they cross the blood-brain barrier and how do they inhibit cell proliferation. 1998 Jun 19. Ann N Y Acad Sci. 845:278-84. National Institute of Neurological Disorders and Stroke Thompson JP. Schengrund CL. Oligosaccharide-derivatized dendrimers: defined multivalent inhibitors of the adherence of the cholera toxin B subunit and the heat labile enterotoxin of E. coli to GM1. 1997 Nov. Glycoconj J. 14(7):837-45. National Institute of Allergy and Infectious Diseases Mummert CM. Schengrund CL. Nonmuscle myosin heavy chain B is recognized by a monoclonal antibody that inhibits GM1-enhanced neuritogenesis. 1997 Feb. J Neurochem. 68(2):596-600. National Institute of Neurological Disorders and Stroke Schengrund CL. DasGupta BR. Hughes CA. Ringler NJ. Ganglioside-induced adherence of botulinum and tetanus neurotoxins to adducin. 1996 Jun. J Neurochem. 66(6):2556-61. National Institute of Allergy and Infectious Diseases National Institute of Diabetes and Digestive and Kidney Diseases National Institute of Neurological Disorders and Stroke Schengrund CL. Evidence that molecules on the surface of one cell can adhere to the oligosaccharide portion of gangliosides on the surface of another cell. 1995 Jan-Feb. Biol Signals. 4(1):1-13. National Institute of Neurological Disorders and Stroke Schengrund CL. Chi X. Sabol J. Griffith JW. Long-term effects of instilled mineral dusts on pulmonary surfactant isolated from monkeys. 1995. Lung. 173(3):197-208. Saulino MF. Schengrund CL. Differential accumulation of gangliosides by the brains of MPTP-lesioned mice. 1994 Feb 15. J Neurosci Res. 37(3):384-91. National Institute of Neurological Disorders and Stroke Saulino MF. Schengrund CL. Effects of specific gangliosides on the in vitro proliferation of MPTP-susceptible cells. 1993 Oct. J Neurochem. 61(4):1277-83. National Institute of Neurological Disorders and Stroke Schengrund CL. DasGupta BR. Ringler NJ. Ganglioside GD3 enhances adherence of botulinum and tetanus neurotoxins to bovine brain synapsin I. 1993 Aug 20. Neurosci Lett. 158(2):159-62. National Institute of Allergy and Infectious Diseases National Institute of Neurological Disorders and Stroke Schengrund CL. Ringler NJ. Dasgupta BR. Adherence of botulinum and tetanus neurotoxins to synaptosomal proteins. 1992 Dec. Brain Res Bull. 29(6):917-24. National Institute of Allergy and Infectious Diseases National Institute of Neurological Disorders and Stroke Fueshko SM. Schengrund CL. Identification of a GM1-binding protein on the surface of murine neuroblastoma cells. 1992 Aug. J Neurochem. 59(2):527-35. National Institute of Neurological Disorders and Stroke Schengrund CL. DasGupta BR. Ringler NJ. Binding of botulinum and tetanus neurotoxins to ganglioside GT1b and derivatives thereof. 1991 Sep. J Neurochem. 57(3):1024-32. National Institute of Allergy and Infectious Diseases National Institute of Neurological Disorders and Stroke Fueshko SM. Schengrund CL. Murine neuroblastoma cells express ganglioside binding sites on their cell surface. 1990 May. J Neurochem. 54(5):1791-7. National Institute of Allergy and Infectious Diseases National Institute of Neurological Disorders and Stroke Schengrund CL. The role(s) of gangliosides in neural differentiation and repair: a perspective. 1990 Jan. Brain Res Bull. 24(1):131-41. National Institute of Allergy and Infectious Diseases National Institute of Neurological Disorders and Stroke Schengrund CL. Ringler NJ. Binding of Vibrio cholera toxin and the heat-labile enterotoxin of Escherichia coli to GM1, derivatives of GM1, and nonlipid oligosaccharide polyvalent ligands. 1989 Aug 5. J Biol Chem. 264(22):13233-7. National Institute of Allergy and Infectious Diseases Schengrund CL. Shochat SJ. Gangliosides in neuroblastomas. 1988 Jun. Neurochem Pathol. 8(3):189-202. National Institute of Allergy and Infectious Diseases National Cancer Institute Schengrund CL. Prouty C. Oligosaccharide portion of GM1 enhances process formation by S20Y neuroblastoma cells. 1988 Jul. J Neurochem. 51(1):277-82. National Institute of Allergy and Infectious Diseases Zagon IS. Schengrund CL. Neuronal and non-neuronal properties of neuroblastoma cells. 1978 Jun. Exp Cell Res. 114(1):159-65.